Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02308085 · ClinicalTrials.gov registry record · NA
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
A NA study of Early Breast Cancer, sponsored by ETOP IBCSG Partners Foundation.
- Active
- Registry status
- NA
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT02308085 is a NA study of Early Breast Cancer that is active but no longer recruiting, run by ETOP IBCSG Partners Foundation. The registered enrollment target is 518 participants, below the 3,557-participant average among 3 other Early Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT02308085, a NA study of Early Breast Cancer, is active but no longer recruiting, sponsored by ETOP IBCSG Partners Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to fertility, pregnancy and breast cancer biology in young women. A psycho-oncological companion study on fertility concerns, psychological well-being and decisional conflicts will be conducted in interested Centers.
Conditions Studied
Interventions
- OTHER Endocrine therapy interruption
Study Locations (20)
Connecticut
- Smilow Cancer Hospital-Derby Care Center - Derby
- Smilow Cancer Hospital Care Center-Fairfield - Fairfield
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
- Yale University - Yale Cancer Centre - New Haven
- Yale-New Haven Hospital North Haven Medical Center - North Haven
- Smilow Cancer Hospital-Orange Care Center - Orange
- Smilow Cancer Hospital-Torrington Care Center - Torrington
- Smilow Cancer Hospital Care Center-Trumbull - Trumbull
- Smilow Cancer Hospital-Waterbury Care Center - Waterbury
Colorado
- University of Colorado Cancer Centre - Anschutz Cancer Pavilion - Aurora
- Rocky Mountain Cancer Center - Boulder
- SCL Health Saint Joseph Hospital - Denver
- Poudre Valley Hospital - Fort Collins
Delaware
- Helen F. Graham Cancer Center - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Medical Oncology Hematology Consultants PA - Newport
- Regional Hematology Oncology Practice Associates - Newport
California
- Cedars Sinai Medical Centre - Los Angeles
- Stanford Cancer Institute - Palo Alto
- Sharp Memorial Hospital - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2014-12-04 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02308085
The ClinicalTrials.gov registry entry for NCT02308085 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,557-participant average among 3 other Early Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is ETOP IBCSG Partners Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Endocrine therapy interruption is the first listed.
NCT02308085 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Connecticut, Colorado, Delaware.
Frequently Asked Questions
What is clinical trial NCT02308085 about?
NCT02308085 is a clinical study titled "Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer". The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no...
What is the current status of trial NCT02308085?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 518 participants. The study started on 2014-12-04. Estimated completion is 2028-12.
What conditions does trial NCT02308085 study?
This clinical trial studies the following conditions: Early Breast Cancer.
What interventions are being tested in trial NCT02308085?
The interventions under investigation include: Endocrine therapy interruption (OTHER).
Who is sponsoring clinical trial NCT02308085?
This trial is sponsored by ETOP IBCSG Partners Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02308085 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RECRUITING · Phase 3
-
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.